Advertisement

Topics

Santhera Announces First Patient Dosing with Omigapil in Congenital Muscular Dystrophy (CMD) and Full Patient Recruitment of CALLISTO Study

03:15 EDT 20 Jul 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Santhera Pharmaceuticals Holding AG / Santhera Announces First Patient Dosing with Omigapil in Congenital Muscular Dystrophy (CMD) and Full Patient Recruitment of CALLISTO Study . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Santhera Announces First Patient Dosing with Omigapil in Congenital Muscular Dystrophy (CMD) and Full Patient Recruitment of CALLISTO Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Congenital Diseases
Congenital conditions are those which are present from birth. They include structural deformities or loss of function in organs such as the <!--LGfEGNT2Lhm-->heart, gut or skeletal system. They can be corrected by <!--LGfEGNT2Lhm-->surgery, m...

Muscular Dystrophy
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...